Stable liquid VEGF antagonist formulations
Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
1. A stable liquid formulation of comprising 100 mg/mL of a VEGF antagonist, which is a dimer comprising two identical poly-peptides comprising amino acids 27-457 of SEQ ID NO:4, 20 mM histidine, 3% polyethylene glycol (PEG) 3350 w/v, 5% sucrose w/v, and 1.5% glycine w/v, at pH 6.3-6.5.
2. The stable liquid formulation of claim 1 consisting of 100 mg/mL of the VEGF antagonist, 20 mM histidine, 3% PEG 3350 w/v, 5% sucrose w/v, and 1.5% glycine w/v at pH 6.3-6.5 in water.